Alessia Calcagni

Dr. Alessia Calcagni

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
GNGennaro Napolitano
Gennaro Napolitano
CMChiara Di Malta
Chiara Di Malta
AEAlessandra Esposito
Alessandra Esposito
MAMariana Eca Guimaraes de Araujo
Mariana Eca Guimaraes de Araujo
SPSalvatore Pece
Salvatore Pece
ABAndrea Ballabio
Andrea Ballabio

3 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAlessia Calcagni
Alessia Calcagni
LSLeopoldo Staiano
Leopoldo Staiano
NZNicolina Zampelli
Nicolina Zampelli
NMNadia Minopoli
Nadia Minopoli
NHNiculin J. Herz
Niculin J. Herz
ABAndrea Ballabio
Andrea Ballabio
Batten disease, one of the most devastating types of neurodegenerative lysosomal storage disorders, is caused by mutations in CLN3. Here, we show that CLN3 is a vesicular trafficking hub connecting the Golgi and lysosome compartments. Proteomic analysis reveals that CLN3 interacts with several endo-lysosomal trafficking proteins, including the cation-independent mannose 6 phosphate receptor (CI-M6PR), which coordinates the targeting of lysosomal enzymes to lysosomes. CLN3 depletion results in mis-trafficking of CI-M6PR, mis-sorting of lysosomal enzymes, and defective autophagic lysosomal reformation. Conversely, CLN3 overexpression promotes the formation of multiple lysosomal tubules, which are autophagy and CI-M6PR-dependent, generating newly formed proto-lysosomes. Together, our findings reveal that CLN3 functions as a link between the M6P-dependent trafficking of lysosomal enzymes and lysosomal reformation pathway, explaining the global impairment of lysosomal function in Batten disease.

18 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NPNunzia Pastore
Nunzia Pastore
THTuong Huynh
Tuong Huynh
NHNiculin J. Herz
Niculin J. Herz
ACAlessia Calcagni
Alessia Calcagni
TKTiemo J. Klisch
Tiemo J. Klisch
ABAndrea Ballabio
Andrea Ballabio
It is well established that pluripotent stem cells in fetal and postnatal liver (LPCs) can differentiate into both hepatocytes and cholangiocytes. However, the signaling pathways implicated in the differentiation of LPCs are still incompletely understood. Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is known to be involved in osteoblast and myeloid differentiation, but its role in lineage commitment in the liver has not been investigated. Here we show that during development and upon regeneration TFEB drives the differentiation status of murine LPCs into the progenitor/cholangiocyte lineage while inhibiting hepatocyte differentiation. Genetic interaction studies show thatSox9, a marker of precursor and biliary cells, is a direct transcriptional target of TFEB and a primary mediator of its effects on liver cell fate. In summary, our findings identify an unexplored pathway that controls liver cell lineage commitment and whose dysregulation may play a role in biliary cancer.

9 June 2025 in The American Journal of Pathology
Verified
Journal Article
Open access
OSOla Shalaby
Ola Shalaby
TOTomoko Ohmori
Tomoko Ohmori
KMKoichiro Miike
Koichiro Miike
STShunsuke Tanigawa
Shunsuke Tanigawa
LKLuh Ade Wilan Krisna
Luh Ade Wilan Krisna
RNRyuichi Nishinakamura
Ryuichi Nishinakamura
The mammalian kidney contains numerous nephrons connected to the collecting ducts, and each nephron consists of a glomerulus, a proximal tubule, the loop of Henle (LoH), and a distal tubule. Folliculin (FLCN) is a causative gene for Birt-Hogg-Dubé (BHD) syndrome, which is characterized by a variety of manifestations including renal cysts and cancer. Although deletion of Flcn in the mouse collecting duct and distal nephron leads to cyst formation, its precise role in the entire nephron remains unclear. We report here that nephron-specific Flcn knockout mice exhibit cystogenesis along the entire nephron segments, most prominent in the LoH, preceded by an irregularly shaped lumen lined by enlarged epithelia. Single-cell RNA sequencing revealed many upregulated genes, especially in the knockout LoH. These genes include those related to lysosomal activity and mTORC1 activation and are likely targets of TFE3/TFEB. While the double Flcn/Tfe3 knockout only ameliorates the glomerular cysts, the double Flcn/Tfeb knockout largely reverses most of the phenotypes along the entire nephron. Thus, Flcn deletion leads to cystogenesis via aberrant TFEB activation. Our findings reveal the essential role of the FLCN-TFEB signaling pathway in nephron development, particularly in LoH, and shed light on the pathogenesis of BHD syndrome.

6 November 2025 in EMBO Reports
Verified
Journal Article
Open access
NDNeuza Domingues
Neuza Domingues
ACAlessia Calcagni
Alessia Calcagni
SFSofia Freire
Sofia Freire
JPJoana Pires
Joana Pires
RCRicardo Casqueiro
Ricardo Casqueiro
NRNuno Raimundo
Nuno Raimundo
Batten disease is characterized by early-onset blindness, juvenile dementia and death within the second decade of life. The most common genetic cause are mutations in CLN3, encoding a lysosomal protein. Currently, no therapies targeting disease progression are available, largely because its molecular mechanisms remain poorly understood. To understand how CLN3 loss affects cellular signaling, we generated human CLN3 knock-out cells (CLN3-KO) and performed RNA-seq analysis. Our multi-dimensional analysis reveals the transcriptional regulator YAP1 as a key factor in remodeling the transcriptome in CLN3-KO cells. YAP1-mediated pro-apoptotic signaling is also increased as a consequence of CLN3 functional loss in retinal pigment epithelia cells, and in the hippocampus and thalamus of Cln3 Δ7/8 mice, an established model of Batten disease. Loss of CLN3 leads to DNA damage, activating the kinase c-Abl which phosphorylates YAP1, stimulating its pro-apoptotic signaling. This novel molecular mechanism underlying the loss of CLN3 in mammalian cells and tissues may pave a way for novel c-Abl-centric therapeutic strategies to target Batten disease.

1 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NDNeuza Domingues
Neuza Domingues
ACAlessia Calcagni
Alessia Calcagni
JPJoana Pires
Joana Pires
SFSofia Roque Freire
Sofia Roque Freire
NHNiculin Joachim Herz
Niculin Joachim Herz
NRNuno Raimundo
Nuno Raimundo
Batten disease is characterized by early-onset blindness, juvenile dementia and death during the second decade of life. The most common genetic causes are mutations in the CLN3 gene encoding a lysosomal protein. There are currently no therapies targeting the progression of the disease, mostly due to the lack of knowledge about the disease mechanisms. To gain insight into the impact of CLN3 loss on cellular signaling and organelle function, we generated CLN3 knock-out cells in a human cell line (CLN3-KO), and performed RNA sequencing to obtain the cellular transcriptome. Following a multi-dimensional transcriptome analysis, we identified the transcriptional regulator YAP1 as a major driver of the transcriptional changes observed in CLN3-KO cells. We further observed that YAP1 pro-apoptotic signaling is hyperactive as a consequence of CLN3 functional loss in retinal pigment epithelia cells, and in the hippocampus and thalamus of CLN3 exΔ7/8 mice, an established model of Batten disease. Loss of CLN3 activates YAP1 by a cascade of events that starts with the inability of releasing glycerophosphodiesthers from CLN3-KO lysosomes, which leads to perturbations in the lipid content of the nuclear envelope and nuclear dysmorphism. This results in increased number of DNA lesions, activating the kinase c-Abl, which phosphorylates YAP1, stimulating its pro-apoptotic signaling. Altogether, our results highlight a novel organelle crosstalk paradigm in which lysosomal metabolites regulate nuclear envelope content, nuclear shape and DNA homeostasis. This novel molecular mechanism underlying the loss of CLN3 in mammalian cells and tissues may open new c-Abl-centric therapeutic strategies to target Batten disease.